Syntis Bio, Inc. (Series A)
Funding Details
Awarder
Inbox
Date Award
July 1, 2025
Vertical
Biopharmaceuticals
Funding URL
View Funding Page
Funding Amount
$33,000,000
Company Info
Traction
SYNT-101 has demonstrated strong pre-clinical safety and weight loss data, as well as clinical advancements in safety, mechanism of action and pathways for controlling weight.
Founders
Rahul Dhanda
Market
Obesity and Rare Diseases
Location
Boston, Massachusetts, United States
Coinvestors
Mansueto Investments, Woori Venture Partners, Apollo Labs, BOLD Capital Partners, W. R. Berkley Corporation, Safar Partners, Portal Innovations, Colorcon Ventures, Cerity Partners Ventures
Company Description

Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide more accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions.

Links
Website
Back to HomeBack to Biopharmaceuticals DealsView Funding Announcement